北美色素沉着症治疗市场预测至 2030 年 - 区域分析 - 按治疗类型（药妆、光疗或激光疗法、微晶换肤术、化学换肤术、冷冻疗法等）、病症（黄褐斑、日光性雀斑、炎症后色素沉着等）和最终用户（医院、皮肤病中心等）

Historic Data: 2020-2021   |   Base Year: 2022   |   Forecast Period: 2023-2030

No. of Pages: 84    |    Report Code: BMIRE00030848    |    Category: Life Sciences

Available Report Formats

pdf-format excel-format pptx-format
Request Free Sample Buy Now
North America Hyperpigmentation Disorder Treatment Market
Free Sample Buy Now
2022 年北美色素沉着症治疗市场价值为 16.9483 亿美元，预计到 2030 年将达到 30.2873 亿美元；预计 2022 年至 2030 年的复合年增长率为 7.5%。

黄褐斑患病率上升推动北美色素沉着症治疗市场发展

黄褐斑是最主要的色素沉着症之一，其特征是面部出现对称的浅色至深色泥褐色斑点，尤其是下巴、上唇、鼻子、前额和脸颊。它在女性和肤色较黑的人群中很常见。颧骨、下颌和面部中央的临床特征在黄褐斑中很常见。日晒、荷尔蒙变化、怀孕、遗传因素、化妆品和药物都与黄褐斑的形成有关。各种研究估计，黄褐斑在普通人群中的总体患病率为 1% 至 50%。55–64% 的黄褐斑病例报告有相同疾病的家族史。此外，据报道，东亚和西班牙裔人群以及 Fitzpatrick 皮肤光型较高（IV 至 VI）的患者患病率更高；居住在受到强烈紫外线辐射的地方的人患病率也更高。

怀孕是黄褐斑的另一个常见原因。这种疾病也会影响服用口服避孕药和激素的女性。雌激素、孕酮和促黑素细胞激素水平通常在妊娠晚期升高，这可能是一个因素。根据美国国家生物技术信息中心 (NCBI) 2023 年 8 月的数据，黄褐斑在育龄妇女中更为常见，在青春期前很少发生；15–50% 的孕妇会出现这种情况，其患病率为 1.5% 至 33%，具体取决于不同地区的人口。因此，黄褐斑患病率的上升引发了对色素沉着治疗的需求。

北美色素沉着障碍治疗市场概览

北美的色素沉着障碍治疗市场分为美国、加拿大和墨西哥。 2023 年，美国占据了北美最大的色素沉着症治疗市场份额。根据《2024 年有色皮肤更新》（一场皮肤病学会议），随着美国西班牙裔、亚裔和非洲裔的国际移民推动民族和种族多样性的增长，美国的人口结构正在发生变化，这也可能会导致 2050 年左右少数族裔人口向菲茨帕特里克 III、IV、V 和 VI 型皮肤人群转变。具体来说，西班牙裔人口预计将成为美国增长最快的人口群体之一，预计将从 2014 年的 5500 万增长到 2060 年的 1.19 亿。深色皮肤更容易患色素沉着症。

过去 10 年，美国的美容手术数量显着增加。根据国际整形外科医师协会 (ISAPS) 的数据，2021 年全球非手术美容手术数量与 2020 年相比增长了 19.9%。强脉冲光 (IPL) 治疗是排名前五的微创美容手术之一，2020 年美国进行了约 827,000 例 IPL 手术。因此，非侵入性手术的技术进步可能会进一步使美国的色素沉着症治疗市场受益。2023 年 3 月，美国食品药品监督管理局 (FDA) 批准 Candela Corporation 的 PicoWay 激光用于治疗咖啡牛奶斑、黄褐斑、雀斑和太田痣。此前，该激光系统已获准用于治疗良性色素病变、痤疮疤痕、皱纹和纹身去除等。

因此，种族和民族多样性的不断增长，以及药妆、化学换肤、冷冻疗法、光疗或激光疗法等非侵入性医学美容程序的发展等因素促进了美国色素沉着症治疗市场的增长。

北美色素沉着症治疗市场收入及预测至 2030 年（百万美元）

北美色素沉着症治疗市场细分

北美色素沉着症治疗市场分为治疗类型、病症、最终用户和国家。

根据治疗类型，北美色素沉着症治疗市场分为药妆、光疗或激光疗法、微晶换肤、化学换肤、冷冻疗法等。 2022 年，药妆品市场占有最大份额。

根据病情，北美色素沉着症治疗市场细分为黄褐斑、日光性雀斑、炎症后色素沉着等。2022 年，黄褐斑细分市场占有最大份额。

根据最终用户，北美色素沉着症治疗市场细分为医院、皮肤病中心等。2022 年，医院细分市场占有最大份额。

按国家/地区划分，北美色素沉着症治疗市场细分为美国、加拿大和墨西哥。 2022 年，美国占据了北美色素沉着症治疗市场的主导份额。

AbbVie Inc、Bayer AG、Galderma SA、L'OREAL SA、Lutronic Co Ltd、Obagi Cosmeceuticals LLC 和 Vivier Pharma Inc 是北美色素沉着症治疗市场的一些领先公司。

North America Hyperpigmentation Disorder Treatment Strategic Insights

Strategic insights for North America Hyperpigmentation Disorder Treatment involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.

strategic-framework/north-america-hyperpigmentation-disorder-treatment-market-strategic-framework.webp
Get more information on this report

North America Hyperpigmentation Disorder Treatment Report Scope

Report Attribute Details
Market size in 2022 US$ 1,694.83 Million
Market Size by 2030 US$ 3,028.73 Million
Global CAGR (2022 - 2030) 7.5%
Historical Data 2020-2021
Forecast period 2023-2030
Segments Covered By 治疗类型
  • 药妆
  • 光疗或激光疗法
  • 微晶换肤术
  • 化学换肤术
  • 冷冻疗法
By 病症
  • 黄褐斑
  • 日光性雀斑
  • 炎症后色素沉着过度
Regions and Countries Covered 北美
  • 美国
  • 加拿大
  • 墨西哥
Market leaders and key company profiles
  • AbbVie Inc
  • Bayer AG
  • Galderma SA
  • LOREAL S.A.
  • Lutronic Co Ltd
  • Obagi Cosmeceuticals LLC
  • Vivier Pharma Inc
  • Pierre Fabre Group
    		•
    Get more information on this report

    North America Hyperpigmentation Disorder Treatment Regional Insights

    The regional scope of North America Hyperpigmentation Disorder Treatment refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.

    geography/north-america-hyperpigmentation-disorder-treatment-market-geography.webp
    Get more information on this report
    Identical Market Reports with other Region/Countries

    The List of Companies - North America Hyperpigmentation Disorder Treatment Market

    1. AbbVie Inc
    2. Bayer AG
    3. Galderma SA
    4. L'OREAL S.A.
    5. Lutronic Co Ltd
    6. Obagi Cosmeceuticals LLC
    7. Vivier Pharma Inc
    8. Pierre Fabre Group
    Frequently Asked Questions
    How big is the North America Hyperpigmentation Disorder Treatment Market?

    The North America Hyperpigmentation Disorder Treatment Market is valued at US$ 1,694.83 Million in 2022, it is projected to reach US$ 3,028.73 Million by 2030.

    What is the CAGR for North America Hyperpigmentation Disorder Treatment Market by (2022 - 2030)?

    As per our report North America Hyperpigmentation Disorder Treatment Market, the market size is valued at US$ 1,694.83 Million in 2022, projecting it to reach US$ 3,028.73 Million by 2030. This translates to a CAGR of approximately 7.5% during the forecast period.

    What segments are covered in this report?

    The North America Hyperpigmentation Disorder Treatment Market report typically cover these key segments-

  • 治疗类型 (药妆, 光疗或激光疗法, 微晶换肤术, 化学换肤术, 冷冻疗法)
  • 病症 (黄褐斑, 日光性雀斑, 炎症后色素沉着过度)

    • What is the historic period, base year, and forecast period taken for North America Hyperpigmentation Disorder Treatment Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the North America Hyperpigmentation Disorder Treatment Market report:

  • Historic Period : 2020-2021
  • Base Year : 2022
  • Forecast Period : 2023-2030
    • Who are the major players in North America Hyperpigmentation Disorder Treatment Market?

    The North America Hyperpigmentation Disorder Treatment Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • AbbVie Inc
  • Bayer AG
  • Galderma SA
  • LOREAL S.A.
  • Lutronic Co Ltd
  • Obagi Cosmeceuticals LLC
  • Vivier Pharma Inc
  • Pierre Fabre Group
    • Who should buy this report?

    The North America Hyperpigmentation Disorder Treatment Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the North America Hyperpigmentation Disorder Treatment Market value chain can benefit from the information contained in a comprehensive market report.

    north-america-hyperpigmentation-disorder-treatment-market